Atlas company financials

BIOMARIN PHARMACEUTICAL INC

Standardized 18-year financial series for BIOMARIN PHARMACEUTICAL INC, built from filing-derived source data and exposed in JSON, CSV, and XLSX so it can feed iterFact artifacts or analyst workflows without hand-entering the numbers.

United StatesCIK 0001048477FY2008 → FY2025

Open JSON Download CSV Download XLSX Quarterly JSON Summary JSON Filing index

Latest fiscal year

FY2025

Revenue

$3.2B

Adjusted EBITDA

—

Net result

$348.9M

Net financial debt

—

Latest source: FY2025 filing · published data snapshot generated April 26, 2026

Phase 2 summary

Latest quarter, TTM, and growth are now pre-computed for chat and templates.

Latest quarter revenue

$776.1M

TTM revenue

$3.1B

TTM free cash flow

—

Latest quarter net result

-$30.7M

Quarterly coverage: 50 periods · latest quarter FY2025-Q3 · TTM revenue growth 21.9%.

What this gives you

A proof-of-concept company data surface, not a dead PDF shelf.

The same standardized payload behind this page is exposed through downloadable CSV and XLSX files plus a stable JSON route. That makes it usable as a live input to iterFact templates, a spreadsheet handoff, or a future API surface without re-normalizing the source documents again.

Source audit

Official links first, raw iterFact payloads right next to them.

Official sources

SEC EDGAR companyfacts
comparative · biomarin-pharmaceutical-inc-fy2008 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2011-02-24 · Retrieved: 2026-04-26T11:48:01.887349+00:00
SEC EDGAR companyfacts
primary · biomarin-pharmaceutical-inc-fy2011 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2012-02-22 · Retrieved: 2026-04-26T11:48:01.887349+00:00
SEC EDGAR companyfacts
primary · biomarin-pharmaceutical-inc-fy2012 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2013-02-26 · Retrieved: 2026-04-26T11:48:01.887349+00:00
SEC EDGAR companyfacts
primary · biomarin-pharmaceutical-inc-fy2013 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2014-02-26 · Retrieved: 2026-04-26T11:48:01.887349+00:00
SEC EDGAR companyfacts
primary · biomarin-pharmaceutical-inc-fy2014 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2015-03-02 · Retrieved: 2026-04-26T11:48:01.887349+00:00

Ten-year series

Headline company financials by fiscal year

Fiscal year	Revenue	Adj. EBITDA	EBIT	Net result	Op. cash flow	Capex	Net debt	Status
FY2008	296M	—	40M	31M	-9M	-56M	—	comparative annual fact carried from later 10k · missing accounts receivable · missing adjusted ebitda · missing current assets · missing current liabilities · missing gross profit · missing inventory · missing net financial debt · missing total assets
FY2009	325M	—	16M	-488K	88M	-90M	—	comparative annual fact carried from later 10k · missing adjusted ebitda · missing gross profit · missing net financial debt
FY2010	376M	—	544K	206M	19M	-49M	—	missing adjusted ebitda · missing gross profit · missing net financial debt
FY2011	441M	—	-34M	-54M	19M	-73M	—	missing adjusted ebitda · missing gross profit · missing net financial debt
FY2012	501M	—	-110M	-114M	18M	-45M	—	missing adjusted ebitda · missing gross profit · missing net financial debt
FY2013	548M	—	-156M	-176M	-60M	-65M	—	missing adjusted ebitda · missing basic eps · missing diluted eps · missing diluted weighted average shares · missing gross profit · missing net financial debt
FY2014	751M	—	-93M	-134M	-74M	-119M	—	missing adjusted ebitda · missing gross profit · missing net financial debt
FY2015	890M	—	-111M	-172M	-222M	-228M	—	missing adjusted ebitda · missing gross profit · missing net financial debt

Filing provenance